Positive Efficiency of Combine Immunotherapy in Immunocompromised Girls with Recurrent Nonspecific Chronic Vulvovaginitis

Nonspecific chronic vulvovaginites (NCVV) are a frequent clinical sign of immune deficiency, especially in young girls. The established problems with the functioning of various parts of the immune system (IS) in this pathology dictate the need to include immunomodulatory therapy into the complex. The developed program of combined immunotherapy for immunocompromised girls allows reducing the severity and duration of exacerbation of NCVV, their frequency against the background of a significant reduction in ARVI incidence. Positive clinical effects were observed with underlying restoration in IS functioning. A protective effect was obtained (observation in a catamnesis for 1 year): the duration of a clinically safe period increased from 6 to 11-11.5 months per year. Introduction Vulvovaginitis takes the first place in the structure of gynaecological disorders in girls of primary school age and preschool age, with the peak share at the age of 2-7 years old. Acute and chronic genital inflammations in childhood may later cause serious infections and inflammations in women of various ages and result in reproductive disorders in women of childbearing age. Therefore tackling the challenge of protecting the reproductive health of children and teenagers, preventing and treating gynaecological disorders in children is a burning issue; it is of huge practical significance and of a certain interest both for scientists and practitioners.